Skip to main content
SpringerLink
Log in

Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?

  • Letter to the Editor
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Querfeld U, Weber LT (2018) Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol. https://doi.org/10.1007/s00467-018-3970-y

  2. Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71–76

    Article  Google Scholar 

  3. Sakuraya K. Kakegawa D, Sakurai S, Hirano D, Fujinaga S (2018) Risk factors associated with relapse and hospitalization during periods of febrile infection in children with nephrotic syndrome treated with immunosuppressant [in Japanese] Nihon Shoni Jinzobyo Gakkai Shi 31:1:25–29

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Saitama Children’s Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama City, Saitama, 330-8777, Japan

    Shuichiro Fujinaga & Koji Sakuraya

Authors
  1. Shuichiro Fujinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koji Sakuraya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichiro Fujinaga.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fujinaga, S., Sakuraya, K. Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?. Pediatr Nephrol 33, 2389–2390 (2018). https://doi.org/10.1007/s00467-018-3993-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-018-3993-4

Search

Navigation